Navigation Links
Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
Date:9/19/2007

rganism from synthesizing proteins. Methionyl tRNA synthetase is a novel target that has not been previously exploited by antibiotics and REP3123 shows no cross-resistance to currently marketed antibacterial agents. To determine the ability of REP3123 to prevent sporulation of C. difficile, four clinical isolates were studied including two epidemic BI/NAP1/027 strains identified in recent outbreaks in Quebec, Canada. The BI/NAP1/027 outbreak strains produce greater amounts of toxins A and B, have increased sporulation capacity, and cause more severe disease and increased morbidity and mortality. All bacterial strains were grown in the presence of low concentrations (sub-minimum inhibitory concentrations or MICs) of either REP3123, vancomycin or metronidazole. Spores were quantified after 96 hours of drug exposure. All four strains of C. difficile varied in their ability to produce spores under the conditions evaluated in this study. At 0.5 times the MIC, REP3123 was the most effective agent at preventing the production of spores in all strains (equal to or less than 1% of spores after 96 hours of treatment). In contrast, sub-MICs of metronidazole promoted spore formation in three strains and vancomycin promoted sporulation in two strains. The ability of REP3123 to inhibit sporulation was concentration-dependent, with no spores detected at concentrations of 0.5 times the MIC. The FDA has not approved REP3123 for marketing in this or any other indication.

"CDAD is a challenging disease for many reasons, including the difficulty associated with eradication of Clostridium difficile and its spores from the environment," explained Stuart Johnson, M.D., Associate Professor of Medicine, Stritch School of Medicine, Loyola University and the Hines VA Medical Center in Chicago. "These results demonstrating that REP3123 has a direct impact on inhibiting spore-formation of C. difficile bacteria are highly promising and clinically relevant."

"Through a novel mechanism
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Inc. (NYSE: HSP ), a leading global ... it will host a conference call to discuss its ... on Thursday, Feb. 4, 2010, at 8 a.m. Central ... full-year 2009 results earlier that morning, before the U.S. ... live webcast of the conference call will be available ...
(Date:12/16/2009)... BAY, Wis., Dec. 16 EuroPharma, ... Biotech for the use of super absorbency ... multiple EuroPharma formulations. The exclusive distribution ... the health food store channel and professional ... doctors, and clinics. BCM-95® is a ...
(Date:12/16/2009)... 16 Boston Scientific Corporation (NYSE: ... Directors has elected Nelda Connors as a Director. ... Electrical and Metal Products division of Tyco International. ... holding several positions in operations and general management. ... number of executive and management capacities with Ford, Chrysler ...
Breaking Medicine Technology:EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 2Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 3New nanotech sensor developed with medical chemistry applications 14461 1New nanotech sensor developed with medical chemistry applications 14461 2Pelosi Announces Key Provision in Health Insurance Reform for Young Adults 59416 1Pelosi Announces Key Provision in Health Insurance Reform for Young Adults 59416 2Pelosi Announces Key Provision in Health Insurance Reform for Young Adults 59416 3Pelosi Announces Key Provision in Health Insurance Reform for Young Adults 59416 4Pelosi Announces Key Provision in Health Insurance Reform for Young Adults 59416 5Pelosi Announces Key Provision in Health Insurance Reform for Young Adults 59416 6Albert Lea Residents Add 3 1 Years of Life Expectancy 59412 1Albert Lea Residents Add 3 1 Years of Life Expectancy 59412 2Albert Lea Residents Add 3 1 Years of Life Expectancy 59412 3Albert Lea Residents Add 3 1 Years of Life Expectancy 59412 4Albert Lea Residents Add 3 1 Years of Life Expectancy 59412 5
(Date:12/16/2009)... Ensure and Encourage Access to Quality, Cost-Effective Care , ... ... of Congress have debated the best ways to rein in runaway ... reform. An important part of the ongoing discussion includes how ... care providers besides doctors of medicine (MDs) or osteopathy (DOs). ...
(Date:12/16/2009)... the global leader of Digital Pen and Paper technology and ... clinical trials, today announced that it is ranked among the ... - EMEA 2009. , ... (PRWEB) ... software solutions for the capture, digitalization and management of handwritten ...
(Date:12/16/2009)... factor for use, expert says, , , WEDNESDAY, Dec. 16 ... much less likely to die when they receive an ... study included 4,685 people, ages 65 to 85, who ... ventricular fraction (a measure of the heart,s pumping ability) ... period, those who were treated with standard medication and ...
(Date:12/16/2009)... 16 Shoppers like knowing if their ... Argentina. But grocers have found it burdensome to ... laws requiring them to provide the information at ... easyCOOLnow.com for easily making grocery and ... provisions that require retailers of unprocessed fruits, vegetables ...
(Date:12/16/2009)... A new software program developed by CareRise will reduce ... calculate their staffing needs as it relates to the ... healthcare facilities to calculate their mandatory nurse-to-patient staffing needs, ... a daily report as to how it affects their ... risk management in the healthcare industry, has been allowed ...
Breaking Medicine News(10 mins):Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News:Implanted Defibrillator Might Extend Life 2Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software 2
... Innovations, Inc. (Nasdaq: YDNT ) today announced that it ... on-demand web cast conference call on Tuesday, April 28, 2009 at ... call will be available through InterCall at http://tinyurl.com/ydnt1QTR09 ... will also be available through the Company,s website, www.ydnt.com ...
... 20 The board of directors of Eli Lilly and ... for the second quarter of 2009 of $0.49 a share ... as was paid in the first quarter and maintains the ... dividend is payable June 10, 2009, to shareholders of record ...
... AMGN ) today announced that it plans to ... 2009 after the close of the financial markets. The announcement ... community at 2 p.m. Pacific Time. Participating in the ... executive officer, and other members of Amgen,s senior management team.Live ...
... study finds 8-ounce glass enhances absorption of rapamycin 3 to ... Grapefruit juice boosts the anti-cancer effects of the drug rapamycin, ... advanced solid tumors, for which there is no effective treatment. ... the drug, as a liquid, once a week. After the ...
... define advantages, limits of procedure, study suggests , , MONDAY, ... useful for removal of certain head and neck cancers, ... with oral cavity, throat or larynx tumors. Of those ... of the cancerous tissue. Negative margins (when no cancer ...
... Mass., April 20 Inverness Medical Innovations, Inc. (NYSE: ... take charge of their health at home through the merger ... will release its first quarter 2009 earnings on Monday, April ... beginning at 10:00 a.m. (Eastern Time) on that date to ...
Other Medicine News:Health News:Young Innovations, Inc. Provides First Quarter Conference Call Details 2Health News:Amgen Announces Webcast of 2009 First Quarter Financial Results 2Health News:Grapefruit Juice Boosts Anti-Cancer Drug's Effects 2Health News:Robotic Surgery Practical for Some Head, Neck Tumors 2Health News:Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 27, 2009 to Discuss First Quarter 2009 Results 2
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... Pick one of our pipettors up and ... and ejector positionsright where they should beeven if ... designed to help avoid repetitive stress injuries caused ... The Palm Of Your Hand Start dispensing ...
... BioControl multichannel has the same ... channel model. The same universal ... and five single channel tip ... a recharge and storage stand ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
Medicine Products: